Adenovirus-mediated p53 gene therapy for human cancer

Toshiyoshi Fujiwara, M. Kataoka, N. Tanaka

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Recent advances in molecular biology have fostered remarkable insights into the molecular basis of neoplasms. Considerable evidence has accumulated that among the mechanisms of human cancer development are overexpression of dominant oncogenes, expression of mutant oncogenes, or specific chromosomal deletions or mutations that induce inactivation of tumor-suppressor genes. This understanding of cancer pathogenesis suggests that restoration of the function of critical gene products could halt or reverse these abnormalities, thus having a therapeutic effect. The p53 tumor suppressor gene has been implicated in many inherited and sporadic forms of malignancies in humans. Preclinical experiments have demonstrated that restoration of wildtype p53 function in the cancer cell by gene transfer is sufficient to cause antitumor effects such as cell-cycle arrest and induction of apoptosis. This approach has entered clinical testing and provided intriguing information about the intratumoral administration of an adenovirus vector expressing the wildtype p53 gene in non-small-cell lung cancer. The clinical study has also provided evidence of the bystander phenomenon, which is important for potential clinical efficacy. This article reviews recent highlights in this rapidly evolving field: p53 gene therapy for human cancer.

Original languageEnglish
Pages (from-to)51-54
Number of pages4
JournalMolecular Urology
Volume4
Issue number2
Publication statusPublished - 2000

Fingerprint

p53 Genes
Adenoviridae
Genetic Therapy
Neoplasms
Tumor Suppressor Genes
Oncogenes
Sequence Deletion
Neoplasm Genes
Human Development
Therapeutic Uses
Cell Cycle Checkpoints
Non-Small Cell Lung Carcinoma
Molecular Biology
Apoptosis
Genes

ASJC Scopus subject areas

  • Urology

Cite this

Adenovirus-mediated p53 gene therapy for human cancer. / Fujiwara, Toshiyoshi; Kataoka, M.; Tanaka, N.

In: Molecular Urology, Vol. 4, No. 2, 2000, p. 51-54.

Research output: Contribution to journalArticle

Fujiwara, T, Kataoka, M & Tanaka, N 2000, 'Adenovirus-mediated p53 gene therapy for human cancer', Molecular Urology, vol. 4, no. 2, pp. 51-54.
Fujiwara, Toshiyoshi ; Kataoka, M. ; Tanaka, N. / Adenovirus-mediated p53 gene therapy for human cancer. In: Molecular Urology. 2000 ; Vol. 4, No. 2. pp. 51-54.
@article{21c53f6c036b4e62b6c2a6eb04bebd74,
title = "Adenovirus-mediated p53 gene therapy for human cancer",
abstract = "Recent advances in molecular biology have fostered remarkable insights into the molecular basis of neoplasms. Considerable evidence has accumulated that among the mechanisms of human cancer development are overexpression of dominant oncogenes, expression of mutant oncogenes, or specific chromosomal deletions or mutations that induce inactivation of tumor-suppressor genes. This understanding of cancer pathogenesis suggests that restoration of the function of critical gene products could halt or reverse these abnormalities, thus having a therapeutic effect. The p53 tumor suppressor gene has been implicated in many inherited and sporadic forms of malignancies in humans. Preclinical experiments have demonstrated that restoration of wildtype p53 function in the cancer cell by gene transfer is sufficient to cause antitumor effects such as cell-cycle arrest and induction of apoptosis. This approach has entered clinical testing and provided intriguing information about the intratumoral administration of an adenovirus vector expressing the wildtype p53 gene in non-small-cell lung cancer. The clinical study has also provided evidence of the bystander phenomenon, which is important for potential clinical efficacy. This article reviews recent highlights in this rapidly evolving field: p53 gene therapy for human cancer.",
author = "Toshiyoshi Fujiwara and M. Kataoka and N. Tanaka",
year = "2000",
language = "English",
volume = "4",
pages = "51--54",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Adenovirus-mediated p53 gene therapy for human cancer

AU - Fujiwara, Toshiyoshi

AU - Kataoka, M.

AU - Tanaka, N.

PY - 2000

Y1 - 2000

N2 - Recent advances in molecular biology have fostered remarkable insights into the molecular basis of neoplasms. Considerable evidence has accumulated that among the mechanisms of human cancer development are overexpression of dominant oncogenes, expression of mutant oncogenes, or specific chromosomal deletions or mutations that induce inactivation of tumor-suppressor genes. This understanding of cancer pathogenesis suggests that restoration of the function of critical gene products could halt or reverse these abnormalities, thus having a therapeutic effect. The p53 tumor suppressor gene has been implicated in many inherited and sporadic forms of malignancies in humans. Preclinical experiments have demonstrated that restoration of wildtype p53 function in the cancer cell by gene transfer is sufficient to cause antitumor effects such as cell-cycle arrest and induction of apoptosis. This approach has entered clinical testing and provided intriguing information about the intratumoral administration of an adenovirus vector expressing the wildtype p53 gene in non-small-cell lung cancer. The clinical study has also provided evidence of the bystander phenomenon, which is important for potential clinical efficacy. This article reviews recent highlights in this rapidly evolving field: p53 gene therapy for human cancer.

AB - Recent advances in molecular biology have fostered remarkable insights into the molecular basis of neoplasms. Considerable evidence has accumulated that among the mechanisms of human cancer development are overexpression of dominant oncogenes, expression of mutant oncogenes, or specific chromosomal deletions or mutations that induce inactivation of tumor-suppressor genes. This understanding of cancer pathogenesis suggests that restoration of the function of critical gene products could halt or reverse these abnormalities, thus having a therapeutic effect. The p53 tumor suppressor gene has been implicated in many inherited and sporadic forms of malignancies in humans. Preclinical experiments have demonstrated that restoration of wildtype p53 function in the cancer cell by gene transfer is sufficient to cause antitumor effects such as cell-cycle arrest and induction of apoptosis. This approach has entered clinical testing and provided intriguing information about the intratumoral administration of an adenovirus vector expressing the wildtype p53 gene in non-small-cell lung cancer. The clinical study has also provided evidence of the bystander phenomenon, which is important for potential clinical efficacy. This article reviews recent highlights in this rapidly evolving field: p53 gene therapy for human cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034086660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034086660&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 51

EP - 54

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 2

ER -